Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Gains from Sales and Divestitures (2016 - 2025)

Viking Therapeutics' Gains from Sales and Divestitures history spans 12 years, with the latest figure at $854220.0 for Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures changed N/A year-over-year to $854220.0; the TTM value through Dec 2025 reached $854220.0, changed N/A, while the annual FY2025 figure was $854220.0, N/A changed from the prior year.
  • Gains from Sales and Divestitures for Q4 2025 was $854220.0 at Viking Therapeutics, up from $62252.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $1.6 million in Q3 2024 and bottomed at $62252.0 in Q3 2025.
  • The 5-year median for Gains from Sales and Divestitures is $347104.0 (2023), against an average of $588242.7.
  • The largest annual shift saw Gains from Sales and Divestitures skyrocketed 276.72% in 2021 before it plummeted 95.99% in 2025.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $270063.0 in 2021, then fell by 17.61% to $222503.0 in 2022, then skyrocketed by 252.85% to $785105.0 in 2023, then skyrocketed by 97.55% to $1.6 million in 2024, then crashed by 44.92% to $854220.0 in 2025.
  • Per Business Quant, the three most recent readings for VKTX's Gains from Sales and Divestitures are $854220.0 (Q4 2025), $62252.0 (Q3 2025), and $668015.0 (Q2 2025).